IDEXX Laboratories stock (US45167R1041): Q1 earnings beat with 14.3% revenue growth

IDEXX Laboratories reported Q1 2026 earnings on May 5, beating EPS estimates by $0.06 at $3.47 and revenue by 14.3% to $1.14 billion. The company issued full-year guidance aligning with consensus.

IDEXX Laboratories released its Q1 2026 earnings on May 5, 2026, reporting earnings per share of $3.47, surpassing the consensus estimate of $3.41 by $0.06. Quarterly revenue increased 14.3% year-over-year to $1.14 billion, exceeding expectations of $1.12 billion, MarketBeat as of May 2026. The company provided full-year EPS guidance of $14.45-$14.90, compared to consensus of $14.52, and revenue guidance of $4.7-$4.8 billion versus $4.7 billion expected.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories, Inc.
• Sector/industry: Healthcare / Diagnostics
• Headquarters/country: United States
• Core markets: Veterinary diagnostics, water testing
• Key revenue drivers: Companion animal diagnostics, livestock/poultry
• Home exchange/listing venue: Nasdaq (IDXX)
• Trading currency: USD

IDEXX Laboratories: core business model

IDEXX Laboratories develops and manufactures diagnostic products and systems for companion animal veterinary, livestock and poultry, dairy and water testing markets. The company operates a razor-razorblade model, selling instruments and recurring consumables, which drives high customer retention and margins, as noted by investors like Baron Funds. Its leading diagnostics menu benefits from heavy R&D investment exceeding competitors.

Headquartered in Westbrook, Maine, IDEXX serves a global customer base with a focus on the US market, where pet ownership trends support growth. The stock trades on Nasdaq under IDXX, providing US investors exposure to veterinary healthcare expansion.

Main revenue and product drivers for IDEXX Laboratories

Companion animal group generated the bulk of Q1 2026 revenue growth at 14.3% to $1.14 billion overall, driven by diagnostics like IDEXX SNAP tests and Catalyst analyzers. Recurring revenue from consumables forms the core, with secular tailwinds from rising pet humanization and preventive care in the US.

Trailing 12-month revenue stood at $4.30 billion with net income of $1.06 billion as of the Q1 report publication on May 5, 2026, MarketBeat as of May 2026. Earnings per share over the last four quarters totaled $13.58.

Industry trends and competitive position

The veterinary diagnostics market benefits from pet spending growth, favorable demographics and increased preventative care focus. IDEXX holds a leading position with superior R&D spend and product portfolio versus peers, per Baron Partners Fund analysis.

Why IDEXX Laboratories matters for US investors

Listed on Nasdaq, IDEXX Laboratories offers US investors direct exposure to the booming $100+ billion US pet industry, where diagnostics penetration is rising. Its strong cash flow supports share repurchases, enhancing shareholder returns amid economic resilience in animal health.

Conclusion

IDEXX Laboratories delivered a solid Q1 2026 earnings beat with revenue and EPS above consensus, alongside in-line full-year guidance. The company's razor-razorblade model and leadership in veterinary diagnostics position it well amid pet care trends. Investors will watch execution on guidance and cash return initiatives in coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.